New cancer pill enters first human safety testing
NCT ID NCT06143007
Summary
This is the first study in humans testing an experimental oral medication called BB3008 for advanced solid tumors. The main goal is to find a safe dose and understand how the body processes the drug in 42 patients whose cancers have progressed despite standard treatments. Researchers will monitor side effects, measure drug levels in the blood, and look for early signs that the treatment might help control tumor growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100005, China
Conditions
Explore the condition pages connected to this study.